4LL Stock Chart & Stats
€5.42
€0.22(2.78%)
At close: 4:00 PM EDT
€5.42
€0.22(2.78%)
Day’s Range― - ―
52-Week Range€3.71 - €8.57
Previous CloseN/A
Volume161.00
Average Volume (3M)1.04K
Market Cap
€980.89M
Enterprise Value€1.80K
Total Cash (Recent Filing)€774.35M
Total Debt (Recent Filing)€1.04B
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Oct 28, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding181,684,020
10 Day Avg. Volume123
30 Day Avg. Volume1,045
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.89
Price to Sales (P/S)0.49
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.60Price Target Upside21.81% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€2.07B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationSustained positive operating and free cash flow gives Teladoc internal funding for operations, product investment, and customer delivery despite accounting losses. This liquidity support reduces reliance on external financing and provides resilience while management works to improve profitability.
Integrated Care Growth And Margin ExpansionIntegrated Care is showing improving operating quality, with modest revenue growth, faster EBITDA expansion, and a materially higher margin. Its 100.3M U.S. members and growing chronic-care enrollment provide a substantial base for recurring utilization and future cross-selling.
Platform And AI InnovationTeladoc 1 and Pulse extend the company’s platform beyond individual virtual visits toward connected care and coordinated clinical intelligence. Broader product capability may deepen customer relationships, support chronic-care expansion, and strengthen differentiation as digital care models mature.
Bears Say
BetterHelp Revenue ContractionBetterHelp’s declining revenue is a durable headwind because the business is losing cash-pay volume faster than insurance growth can replace it. The reduced full-year outlook lowers consolidated growth and makes near-term earnings improvement more dependent on a successful transition.
Insurance Conversion Constrained By Provider CapacityProvider capacity limits Teladoc’s ability to convert rising insurance demand into billable sessions and revenue. Because availability varies by state, payer, appointment, and time, scaling the new model may remain uneven, extending the period of pressure on BetterHelp’s economics.
Negative Profitability And Weak Top-line TrendTeladoc has improved from its much larger prior losses but remains below break-even, while weak or declining revenue limits operating leverage. Continued losses reduce confidence in durable earnings power and make margin recovery dependent on renewed growth and sustained cost discipline.
Teladoc News
4LL FAQ
What was Teladoc’s price range in the past 12 months?
Teladoc lowest stock price was €3.71 and its highest was €8.57 in the past 12 months.
What is Teladoc’s market cap?
Teladoc’s market cap is €980.89M.
When is Teladoc’s upcoming earnings report date?
Teladoc’s upcoming earnings report date is Oct 28, 2026 which is in 49 days.
How were Teladoc’s earnings last quarter?
Teladoc released its earnings results on Jul 29, 2026. The company reported -€0.181 earnings per share for the quarter, beating the consensus estimate of -€0.215 by €0.034.
Is Teladoc overvalued?
According to Wall Street analysts Teladoc’s price is currently Undervalued.
Does Teladoc pay dividends?
Teladoc does not currently pay dividends.
What is Teladoc’s EPS estimate?
Teladoc’s EPS estimate is -0.19.
How many shares outstanding does Teladoc have?
Teladoc has 181,684,020 shares outstanding.
What happened to Teladoc’s price movement after its last earnings report?
Teladoc reported an EPS of -€0.181 in its last earnings report, beating expectations of -€0.215. Following the earnings report the stock price went down -30.585%.
Which hedge fund is a major shareholder of Teladoc?
Currently, no hedge funds are holding shares in DE:4LL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teladoc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€6.60 (21.81% Upside)
€6.60 (21.81% Upside)
Blogger Sentiment
Bullish
DE:4LL Sentiment 61%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Teladoc
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
4LL Company Deck
4LL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: clear strength and margin expansion in Integrated Care, meaningful product and AI-driven innovation (Teladoc 1 and Pulse), strong liquidity and disciplined cost actions. Offsetting these positives were material near-term challenges in BetterHelp as the business transitions from cash-pay to an insurance/in-network model — accelerated declines in cash-pay users, provider capacity constraints that limited insurance conversion, and a downward revision to consolidated revenue guidance. Management has taken decisive actions (national insurance rollout, provider recruitment/activation initiatives, lower ad spend) to address the issues, but execution risk and timing remain. Overall, the results show operational progress in core businesses and constructive steps to fix the BetterHelp transition, balanced by meaningful short-term revenue pressure and uncertainty in that segment.View all DE:4LL earnings summaries4LL Revenue Breakdown
56.44% Teladoc Health Integrated Care
43.56% BetterHelp
4LL Stock 12 Month Forecast
Average Price Target
€6.60
▲(21.81% Upside)
Technical Analysis
American Well
―
Doximity
―
VSee Health
―
Hinge Health, Inc. Class A
―
Omada Health, Inc.
―